Marksans Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 5,600.13 million compared to INR 4,859.76 million a year ago. Revenue was INR 5,765.42 million compared to INR 4,969.85 million a year ago. Net income was INR 782.9 million compared to INR 819.32 million a year ago. Basic earnings per share from continuing operations was INR 1.73 compared to INR 1.97 a year ago. Diluted earnings per share from continuing operations was INR 1.73 compared to INR 1.97 a year ago.
For the full year, sales was INR 21,774.07 million compared to INR 18,521.39 million a year ago. Revenue was INR 22,278.29 million compared to INR 19,114.52 million a year ago. Net income was INR 3,137 million compared to INR 2,663.08 million a year ago. Basic earnings per share from continuing operations was INR 6.92 compared to INR 6.41 a year ago. Diluted earnings per share from continuing operations was INR 6.92 compared to INR 6.41 a year ago.